Oncology Trial Design And Study Build
Source: Veeva Systems, Inc.
By Richard Young, Vice President, Vault CDMS
Clinical trial durations of oncology drugs are 30%-40% longer than other drug trials, due to more complex designs and difficulty finding, enrolling, and retaining study volunteers (Tufts CSDD, 2021). Unscheduled, flexible, repeat assessments create variability that further complicates design.
Oncology trials are becoming increasingly complex and require more sophisticated trial designs. They often need to be based on adaptive trial principles. EDC technologies haven’t kept up with these new challenges, until now.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Veeva Systems, Inc.
This website uses cookies to ensure you get the best experience on our website. Learn more